vibsanin-a and Leukemia--Myeloid

vibsanin-a has been researched along with Leukemia--Myeloid* in 1 studies

Other Studies

1 other study(ies) available for vibsanin-a and Leukemia--Myeloid

ArticleYear
Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation.
    Cancer research, 2016, 05-01, Volume: 76, Issue:9

    All-trans retinoic acid (ATRA)-based cell differentiation therapy has been successful in treating acute promyelocytic leukemia, a unique subtype of acute myeloid leukemia (AML). However, other subtypes of AML display resistance to ATRA-based treatment. In this study, we screened natural, plant-derived vibsane-type diterpenoids for their ability to induce differentiation of myeloid leukemia cells, discovering that vibsanin A potently induced differentiation of AML cell lines and primary blasts. The differentiation-inducing activity of vibsanin A was mediated through direct interaction with and activation of protein kinase C (PKC). Consistent with these findings, pharmacological blockade of PKC activity suppressed vibsanin A-induced differentiation. Mechanistically, vibsanin A-mediated activation of PKC led to induction of the ERK pathway and decreased c-Myc expression. In mouse xenograft models of AML, vibsanin A administration prolonged host survival and inhibited PKC-mediated inflammatory responses correlated with promotion of skin tumors in mice. Collectively, our results offer a preclinical proof of concept for vibsanin A as a myeloid differentiation-inducing compound, with potential application as an antileukemic agent. Cancer Res; 76(9); 2698-709. ©2016 AACR.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Differentiation; Diterpenes; Enzyme Activation; Humans; Leukemia, Myeloid; Male; Mice; Mice, Inbred C57BL; Phytotherapy; Protein Kinase C; Real-Time Polymerase Chain Reaction; Xenograft Model Antitumor Assays

2016